1
Macrophages can be activated in situ by interaction with liposomes containing various immunomodulators.
2
Thus, DCs have been regarded as a major target for the development of immunomodulators.
3
Development of topical immunization and immunomodulators are under way.
4
Additionally, these results were unchanged in patients treated with biologic monotherapy or combination therapy with immunomodulators.
5
Initial CRP was also associated with the need for immunomodulators in patients with UC at 1-year follow-up.
6
Biodegradable particles loaded with disease-specific antigen, either alone or with immunomodulators, have been reported to ameliorate disease.
7
Moreover, combinations of immunomodulators and pathway inhibitors are expected to be very active, and phase-III trials are planned.
8
CRP and PCDAI at diagnosis were associated with the need for immunomodulators at 1 year in children with CD.
9
We investigated the effects of combination therapy with antibiotics and immunomodulators in patients with IBD and C difficile infection.
10
Patients in clinical remission who are receiving immunomodulators should be assessed for mucosal healing within 1 year of treatment initiation.
11
Conclusions: Patients with IBD that also have C difficile infection are frequently treated with a combination of antibiotics and immunomodulators.
12
Over the past decade, several immunomodulators have demonstrated clinical effectiveness, and three of them have already been approved for use in oncology.
13
The antibody-mediated targeted delivery of cytokines, growth factors and immunomodulators offers great potential for the therapy of cancer and other serious conditions.
14
Thus, eicosanoids present during acute infection may act as immunomodulators aiding the transition to and maintenance of the chronic phase of the disease.
15
The inhibitory effect, mediated by patients adherent cells, was abolished by blocking with indomethacin prostaglandins, that are potent local immunomodulators released by adherent cells.
16
These results suggest that Aloe vera gel contains at least two small molecular weight immunomodulators that may prevent UVB-induced immune suppression in the skin.